• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.

作者信息

Hahn Virginia Shalkey, Lenihan Daniel J, Ky Bonnie

机构信息

Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

出版信息

J Am Heart Assoc. 2014 Apr 22;3(2):e000665. doi: 10.1161/JAHA.113.000665.

DOI:10.1161/JAHA.113.000665
PMID:24755151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4187516/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/539d/4187516/48d87b19aefa/jah3-3-e000665-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/539d/4187516/a93b86abbcb5/jah3-3-e000665-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/539d/4187516/48d87b19aefa/jah3-3-e000665-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/539d/4187516/a93b86abbcb5/jah3-3-e000665-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/539d/4187516/48d87b19aefa/jah3-3-e000665-g2.jpg

相似文献

1
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.癌症治疗引起的心脏毒性：基本机制与潜在的心脏保护疗法。
J Am Heart Assoc. 2014 Apr 22;3(2):e000665. doi: 10.1161/JAHA.113.000665.
2
Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.预防乳腺癌治疗相关心脏毒性的心脏保护策略。
Trends Cardiovasc Med. 2020 Jan;30(1):22-28. doi: 10.1016/j.tcm.2019.01.006. Epub 2019 Jan 29.
3
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.人表皮生长因子受体2（HER2）靶向治疗所致心脏毒性
J Am Heart Assoc. 2017 Sep 22;6(9):e006915. doi: 10.1161/JAHA.117.006915.
4
Anthracycline Chemotherapy and Cardiotoxicity.蒽环类化疗药物与心脏毒性
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75. doi: 10.1007/s10557-016-6711-0.
5
Anthracycline cardiotoxicity: from bench to bedside.蒽环类药物心脏毒性：从 bench 到 bedside。 注：bench 直译为“实验台”，bedside 直译为“床边”，这里意译为从基础研究到临床应用。
J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401.
6
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.心脏肿瘤学中的个性化医学：诱导多能干细胞的作用。
Cardiovasc Res. 2019 Apr 15;115(5):949-959. doi: 10.1093/cvr/cvz024.
7
Cardiotoxicity due to targeted anticancer agents: a growing challenge.靶向抗癌药物引起的心脏毒性：日益严峻的挑战。
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719843435. doi: 10.1177/1753944719843435.
8
Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer.心脏肿瘤学：癌症患者最佳心脏检测与心脏保护的临床与影像学视角
Arch Cardiovasc Dis. 2019 Oct;112(10):550-558. doi: 10.1016/j.acvd.2019.07.001. Epub 2019 Sep 12.
9
Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.信号转导治疗中的心脏毒性：erbB2抗体与心脏
Semin Oncol. 2001 Oct;28(5 Suppl 16):18-26. doi: 10.1016/s0093-7754(01)90278-7.
10
GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.GATA4 靶向化合物在体外和体内显示出对抗阿霉素诱导的毒性的心脏保护作用：用人诱导多能干细胞衍生的心肌细胞建立慢性心脏毒性模型。
Arch Toxicol. 2020 Jun;94(6):2113-2130. doi: 10.1007/s00204-020-02711-8. Epub 2020 Mar 17.

引用本文的文献

1
Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies.乳腺癌治疗中的心脏毒性：风险、机制及预防策略。
Med Sci (Basel). 2025 Aug 14;13(3):130. doi: 10.3390/medsci13030130.
2
The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对癌症患者化疗所致心脏毒性和死亡率的影响：一项系统评价和荟萃分析
Cardiooncology. 2025 May 27;11(1):50. doi: 10.1186/s40959-025-00343-4.
3
Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients.

本文引用的文献

1
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.第二代人抗ErbB2免疫核糖核酸酶对曲妥珠单抗耐药肿瘤和心脏细胞的影响。
Protein Eng Des Sel. 2014 Mar;27(3):83-8. doi: 10.1093/protein/gzt065. Epub 2014 Jan 12.
2
DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.拓扑异构酶II毒物诱导的DNA损伤反应（DDR）需要小GTP酶Rac的核功能。
Biochim Biophys Acta. 2013 Dec;1833(12):3093-3103. doi: 10.1016/j.bbamcr.2013.08.016. Epub 2013 Aug 30.
3
Emerging paradigms in cardiomyopathies associated with cancer therapies.
药物代谢相关基因变异对乳腺癌患者蒽环类化疗所致亚临床心脏毒性的影响。
Int J Mol Sci. 2025 Apr 25;26(9):4051. doi: 10.3390/ijms26094051.
4
Cardiotoxicity of breast cancer drug treatments.乳腺癌药物治疗的心脏毒性
Transl Oncol. 2025 May;55:102352. doi: 10.1016/j.tranon.2025.102352. Epub 2025 Mar 15.
5
Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase.阿霉素诱导的迟发性心脏毒性理论的演变——拓扑异构酶的作用
Int J Mol Sci. 2024 Dec 18;25(24):13567. doi: 10.3390/ijms252413567.
6
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial.预防乳腺癌和淋巴瘤患者的心脏损伤：PROACT临床试验
JACC CardioOncol. 2024 Aug 27;6(5):684-696. doi: 10.1016/j.jaccao.2024.07.010. eCollection 2024 Oct.
7
Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease.他汀类药物在减轻抗癌治疗相关心血管疾病中的作用。
Int J Mol Sci. 2024 Sep 22;25(18):10177. doi: 10.3390/ijms251810177.
8
Expanding roles of circRNAs in cardiovascular diseases.环状RNA在心血管疾病中的作用不断扩展。
Noncoding RNA Res. 2024 Feb 5;9(2):429-436. doi: 10.1016/j.ncrna.2024.02.001. eCollection 2024 Jun.
9
Multi-parameter cardiac magnetic resonance imaging detects anthracycline-induced cardiotoxicity in rabbits model.多参数心脏磁共振成像检测兔模型中蒽环类药物诱导的心脏毒性。
Heliyon. 2023 Nov 12;9(11):e21845. doi: 10.1016/j.heliyon.2023.e21845. eCollection 2023 Nov.
10
Wnt10b protects cardiomyocytes against doxorubicin-induced cell death via MAPK modulation.Wnt10b 通过调节 MAPK 保护心肌细胞免受阿霉素诱导的细胞死亡。
PLoS One. 2023 Oct 19;18(10):e0277747. doi: 10.1371/journal.pone.0277747. eCollection 2023.
与癌症治疗相关的心肌病的新兴范式。
Circ Res. 2013 Aug 30;113(6):754-64. doi: 10.1161/CIRCRESAHA.113.300218.
4
The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist.β受体阻滞剂奈必洛尔是一种 G 蛋白偶联受体激酶/β-arrestin 偏向激动剂。
PLoS One. 2013 Aug 20;8(8):e71980. doi: 10.1371/journal.pone.0071980. eCollection 2013.
5
Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy.依那普利拉增加 PPARβ/δ 的表达，而对 PPARα 和 PPARγ 没有影响，并调节柔红霉素诱导的心肌病亚急性模型中的心脏功能。
Eur J Pharmacol. 2013 Aug 15;714(1-3):472-7. doi: 10.1016/j.ejphar.2013.06.040. Epub 2013 Jul 5.
6
An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.一种工程化的双价神经调节素可预防多柔比星引起的心脏毒性，并降低潜在致瘤性。
Circulation. 2013 Jul 9;128(2):152-61. doi: 10.1161/CIRCULATIONAHA.113.002203. Epub 2013 Jun 11.
7
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.冠状动脉微血管周细胞是马来酸舒尼替尼诱导心脏毒性的细胞靶标。
Sci Transl Med. 2013 May 29;5(187):187ra69. doi: 10.1126/scitranslmed.3005066.
8
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).依那普利和卡维地洛预防恶性血液病患者化疗引起的左心室收缩功能障碍：OVERCOME 试验（依那普利和卡维地洛预防接受强化化疗治疗恶性血液病患者左心室功能障碍）。
J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10.
9
Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer.运动疗法作为早期癌症诊断后心血管和肿瘤疾病的治疗方法。
Semin Oncol. 2013 Apr;40(2):218-28. doi: 10.1053/j.seminoncol.2013.01.001.
10
Strategies to prevent and treat cardiovascular risk in cancer patients.预防和治疗癌症患者心血管风险的策略。
Semin Oncol. 2013 Apr;40(2):186-98. doi: 10.1053/j.seminoncol.2013.01.008.